The deal did not include the FT Group's 50 per cent stake in The Economist magazine.

"Pfizer's proposal would dramatically dilute AstraZeneca shareholders' exposure to our unique pipeline and would create risks around its delivery," Chairman Leif Johansson said.

The company has $2 billion tax dispute with the income tax department.